Document Detail


Off-label use of rituximab in systemic lupus erythematosus: a systematic review.
MedLine Citation:
PMID:  20155295     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two significant RCTs have reported negative findings, reopening the debate on clinical benefit. This review of the available data suggests that rituximab induces B-cell depletion in 95% of patients, and a significant reduction in disease activity is achieved with a relatively good safety profile in patients with SLE.
Authors:
Eleanor Murray; Martin Perry
Related Documents :
517385 - Head and neck manifestations of sle.
20090495 - Lupus miliaris disseminatus faciei of the eyelids: report of two cases.
7874925 - Linkage analysis of malignancy-associated sarcoidosis.
19629625 - Subarachnoid hemorrhage in systemic lupus erythematosus in japan: two case reports and ...
9152695 - Traumatic radial head dislocation in children--a missed injury.
19355285 - Realities of publishing in a journal: why should you submit, what should you submit, an...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-02-13
Journal Detail:
Title:  Clinical rheumatology     Volume:  29     ISSN:  1434-9949     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-05-31     Completed Date:  2010-10-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  707-16     Citation Subset:  IM    
Affiliation:
Western Infirmary General, G-3/4, Glasgow, G11 6NT, UK. eleanormurray@doctors.org.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / adverse effects,  pharmacology,  therapeutic use*
B-Lymphocytes / cytology,  drug effects,  immunology
Down-Regulation / drug effects
Humans
Lupus Erythematosus, Systemic / drug therapy*
Off-Label Use*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Artificial organs: recent progress in metals and ceramics.
Next Document:  Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aur...